American Origin Unverified
This profile is unclaimed and has not been independently reviewed.
Claim & get verified
EDAP TMS SA
$4.32
+2.86%
NASDAQ: EDAP · 15-min delayed
$70.5MRevenue · FY2025
-$29.2MNet income
EDAPNASDAQ
About EDAP TMS SA
EDAP TMS SA is an American company.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Reported figures
Financial summary
- Revenue FY2025
- $70.5M
- Net income
- -$29.2M
- Total assets
- $79.0M
- Gross margin
- 42.5%
- Operating margin
- -35.0%
- Net margin
- -41.5%
Source: SEC EDGAR · updated Jun 8, 2026
FY 2025
Financial statements
Income statement
- Revenue
- $70.5M
- Cost of revenue
- $40.5M
- Gross profit
- $30.0M
- Operating expenses
- $54.7M
- Operating income
- -$24.7M
- Income tax
- $438.0K
- Net income
- -$29.2M
- EPS (basic)
- $-0.78
- EPS (diluted)
- $-0.78
Balance sheet
- Total assets
- $79.0M
- Current assets
- $57.2M
- Total liabilities
- $59.6M
- Current liabilities
- $37.1M
- Shareholders’ equity
- $19.4M
Cash flow
- Operating cash flow
- -$16.4M
- Investing cash flow
- -$5.7M
- Financing cash flow
- $8.6M
- Net cash flow
- -$10.5M
Statements via Polygon.io (SEC filings)
NASDAQ: EDAP
$4.32
+2.86%
15-minute delayed · data by Polygon.io
Past year
$1.25
$4.91
52-week range
- EPS (diluted)
- $-0.78
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
Market data by Polygon.io · prices are 15-minute delayed
Auto-generated
At a glance
- Reported a net loss of $29.2M in FY2025.
- Gross margin of 42.5%, net margin -41.5%.
- Trading 12% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review EDAP TMS SA.
Write a review
Newsroom
News about EDAP TMS SA
EDAP to Present at Piper Sandler 37th Annual Healthcare Conference
EDAP to Announce Third Quarter 2025 Financial Results on November 6, 2025
Focal One® HIFU Receives Prestigious Innovation Award
EDAP Receives HIFU Reimbursement for Prostate Cancer in France
EDAP Announces Positive Results from the FARP Randomized Controlled Trial Presented at the American Urological Association (AUA) Annual Meeting
EDAP to Announce Fourth Quarter and Full Year 2024 Financial Results on March 27, 2025
News & sentiment via Polygon.io
Explore
Browse all →
